Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.

Furthermore, in our study, we were able to obtain enough statistical power to determine that even if afatinib is the most expensive treatment, the increased monetary expenditure is compensated with increased effectiveness, although this increased effectiveness did not reach statistical significance.

also in 111,027 other papers